Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q93099
UPID:
HGD_HUMAN
Alternative names:
Homogentisate oxygenase; Homogentisic acid oxidase; Homogentisicase
Alternative UPACC:
Q93099; A8K417; B2R8Z0
Background:
Homogentisate 1,2-dioxygenase, also known as Homogentisate oxygenase, plays a crucial role in the breakdown of amino acids phenylalanine and tyrosine. It catalyzes the conversion of homogentisate to maleylacetoacetate, a key step in the catabolic pathway. This enzyme's malfunction is directly linked to Alkaptonuria, a metabolic disorder characterized by urine that darkens upon standing and severe arthritis.
Therapeutic significance:
The direct association of Homogentisate 1,2-dioxygenase with Alkaptonuria highlights its therapeutic significance. Targeting this enzyme could lead to innovative treatments for Alkaptonuria, focusing on enzyme replacement or enhancement to correct the metabolic pathway.